OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers & Dementia is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
2020 Alzheimer's disease facts and figures	1644
2021 Alzheimer's disease facts and figures	1512
2022 Alzheimer's disease facts and figures	1056
2023 Alzheimer's disease facts and figures	450
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)	356
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019	315
World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia	248
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET	165
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease	164
Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease	163
COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US	156
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease	153
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study	151
Global estimates on the number of persons across the Alzheimer's disease continuum	139
The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning	132
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis	120
Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage	115
Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future	115
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum	111
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research	108
Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues	103
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia	102
Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Worksho	102
Alzheimer's‐like signaling in brains of COVID‐19 patients	100
GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease	94

Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta‐analysis	91
A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6‐month RCT	88
Retinal imaging in Alzheimer's and neurodegenerative diseases	86
Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL‐1β drives amplified responses in primed astrocytes and neuronal network dysfunction	85
The Brain Chart of Aging: Machine‐learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans	85
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia	83
Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis	83
World Alzheimer Report 2019: Attitudes to dementia, a global survey	82
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities	81
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease	79
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) wor	79
Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank	78
Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study	77
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study	76
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis	74
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis	73
An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum	73
36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease	70
Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance	69
Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia	69
Diagnostic criteria for apathy in neurocognitive disorders	68
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau	68
The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019	64
Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients	64
The impact of diabetes on cognitive impairment and its progression to dementia	64
Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics	63
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel	63
Dementia in Latin America: Paving the way toward a regional action plan	61
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging	59
Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation	56
Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study	55